Last week’s hot topic on pulmonary fibrosis was IPF Drug in Phase 2 Study Reduced Lung Fibrosis, Improved Function in 35% of Patients written by Margarida Azevedo.
FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated that the monoclonal antibody agent was able to reduce lung fibrosis in a portion of the IPF patients enrolled, to improve overall lung function.
The results were published in the European Respiratory Journal, in an article titled “FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in IPF.”
Based on the results, the company is planning further investigation of FG-3019 in another Phase 2 study, this time placebo-controlled. The clinical trial (NCT01890265) is now recruiting participants at 25 sites across the U.S. and one in Quebec City, Canada.